Navigation Links
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
Date:7/13/2009

LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first and only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key findings were unveiled at the National Strength and Conditioning Association (NSCA) conference in Las Vegas, NV.

GNC's Amplified Maxertion N.O.(TM) was shown to increase power output at the onset of neuromuscular fatigue by an average of 20% and improve physical performance by helping athletes push past their normal point of exhaustion. This product is designed to increase nitric oxide levels in the body causing a hemodilation effect which expands blood vessels, allowing more blood, oxygen and nutrients to flow to muscles.

"This is truly groundbreaking research that has resulted in the delivery of a truly novel and clinically-validated product to the industry," said Guru Ramanathan, SVP Technology and Product Innovation for GNC. "Using advanced technology and ingredients, this is the first Nitric Oxide enhancing product to demonstrate significant athletic performance effects that are relevant and meaningful to all types of athletes."

The purpose of the double-blind placebo-controlled study was to examine the effects of daily administration of arginine-based supplements on the physical working capacity at the fatigue threshold (PWC(FT)). The PWC(FT) test estimates the highest power output that can be maintained without neuromuscular evidence of fatigue.

Using a cycle ergometer (stationary bicycle), all subjects performed an incremental test to exhaustion prior to supplementation and after four weeks of supplementation. Key study findings demonstrate significant mean increases in PWC(FT) for the 1.5 gm (22.4%) and 3.0 gm (18.8%) supplement groups, but no change for the placebo group (-1.6%).

The study followed 50 college-aged males over the course of four weeks who were randomized into one of three groups - a. placebo (microcrystalline cellulose), b. 1.5 gm of micronized arginine and 300 mg of grape seed extract, and c. 3.0 gm of micronized arginine and 300 mg of grape seed extract.

Amplified Maxertion N.O. is part of a comprehensive line of eight new advanced muscle performance and sports nutrition products from GNC. The entire Pro Performance(R) AMP line was developed through rigorous clinical research and is designed to suit the needs of a wide range of dedicated athletes, from the weekend warrior to the ultra competitive athlete.

About GNC

GNC, headquartered in Pittsburgh, Pa., is the largest global specialty retailer of nutritional products including vitamin, mineral, herbal and other specialty supplements and sports nutrition, diet and energy products. As of March 31, 2009, GNC has more than 5,200 retail locations throughout the United States (including 944 franchise and 1,733 Rite Aid store-within-a-store locations) and franchise operations in 44 international markets. The company -- which is dedicated to helping consumers Live Well -- also offers products and product information online at www.gnc.com.


'/>"/>
SOURCE GNC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oregon Tourism Commission Unveils New Online Customer Service Training Program
2. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
3. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
4. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
5. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 ... evaluating efficacy and safety of CTL019, an investigational ... in relapsed/refractory (r/r) pediatric and young adult patients ... presented today during an oral session at the ... (Abstract #221, December 3, 4:00-5:30 p.m.). The global ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
(Date:12/2/2016)... Calif. (PRWEB) , ... December 02, 2016 , ... On ... at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who ... neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel therapy ... MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason ... extensive financial and operational leadership experience to Advanced Inc. He began his career in ...
(Date:12/2/2016)... ... 02, 2016 , ... The annual time frame to change Medicare health and ... ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current ... need to make changes during this period order for their new policy to go ...
Breaking Medicine News(10 mins):